Clinical Trials

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06114940 2026-03-05

PLUTO

17 enrolled

Carcinoma, Renal Cell

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Cholangiocarcinoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

60 enrolled

Other solid neoplasm

Solid Tumors

NCT06669572 2026-02-17

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

25 enrolled

Carcinoma, Renal Cell

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05846724 2026-01-22

PULSAR

Phase 2 Withdrawn

Sarcoma

Sarcoma, Kaposi

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06138496 2026-01-05

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

39 enrolled

Carcinoma, Renal Cell

NCT05286437 2025-12-30

LaPemERLA

40 enrolled

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Uterine Cervical Neoplasms

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT04207086 2025-12-16

Neo PeLe

21 enrolled

Melanoma

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Carcinoma, Renal Cell

NCT06230471 2025-12-09

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

60 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

29 enrolled

BTC

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

CNSDermatologicGenitourinary

18 enrolled

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT05282901 2025-11-24

PLUME

51 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT04887805 2025-11-19

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT04869137 2025-10-31

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05064280 2025-10-09

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

64 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT05168163 2025-09-16

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

122 enrolled

Carcinoma, Hepatocellular

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

3 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase 2 Completed

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

48 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07070700 2025-08-12

CASTLE-ZS-02

56 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

High Grade Fallopian Tube Serous Adenocarcinoma

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

35 enrolled

Thoracic

NSCLC

NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

10 enrolled

CNS

Meningeal Carcinomatosis

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast

Breast Neoplasms

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

6 enrolled 11 charts